NOV 15, 2018 10:30 AM PST

Management of HPV-Positive Women by QIAsure Methylation Test

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • CEO Self-Screen, Emeritus Professor of Pathology, VUmc
    Biography
      hris Meijer MD, PhD, has been a surgical pathologist since 1977. He performs translational research in the field of oncology with emphasis on HPV and HPV-associated cancers. He was chairman of the Department of Pathology, VU-UMC Amsterdam from 1983-2010 and has been awarded for his research on numerous occasions by (Inter)national organizations.
      Presently, he leads a research group focusing on the development of a full molecular cervical cancer self-screening algorithm and is a part-time director of Self-Screen bv, a company that develops diagnostic molecular tests for cervical (pre)cancer.

    Abstract

    Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that cervical cancer is caused by persistent infections with the human papilloma virus, termed high-risk HPV. In these persistent infections, there is a characteristic cumulative process called hypermethylation, which can eventually silence some critical tumour suppressor genes of the host cells.

    Only around 20% of CIN2/3 lesions will progress to cancer, but still the majority of these are overtreated by ablative therapy leading to comorbidity, especially for women in their child bearing years. 

    Hypermethylation of FAM 19A4 and miR124-2 have been shown to be reliable markers of disease progression, and can be used to determine if a CIN2/3 lesion is transforming into carcinoma.

    QIAGEN´s QIAsure Methylation Test identifies cervical cancer and the preceding CIN lesion with high short-term progression risk. It has been validated in six different European screening settings as a triage test applicable for both HPV and/or cytology screened populations. It brings valuable benefits for the physician, the patient and has proven to improve cost effectiveness for health care organizations and insurance companies.


    Show Resources
    You May Also Like
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    Loading Comments...
    Show Resources
    Attendees
    • See more